Probe • Vol LXII • No. 3 • May–Aug 2023 • 17 urine, flatulence, dyspepsia, jaundice, and weight loss compared with those in the control group. Biochemical profile • Serum bilirubin: In 9 patients in the Liv.52 group, the serum bilirubin level reduced and returned to normal in 6 months, whereas no improvement was observed in the control group within that time frame. • ALP: In 9 patients in the Liv.52 group, the ALP level improved and returned to normal in 6 months, whereas no such improvement was observed in the control group within that period. • SGOT and SGPT: In the Liv.52 group, SGOT and SGPT levels decreased in 21 patients (87.5%) in 12 months, whereas there was only a slight improvement in the control group during the same time. Group C: liver cirrhosis Clinical improvement Most patients in the Liv.52 group experienced alleviation in the signs and symptoms of cirrhosis compared with those in the control group. Biochemical profile • Serum bilirubin: In the Liv.52 group, the serum bilirubin level returned to normal in 13 patients in 12 months. • APL: In the Liv.52 group, the ALP level became normal in 4 patients in 9 to 12 months, and in 10 patients it became normal within 18 to 24 months. • Serum albumin/globulin: In the Liv.52 group, the serum albumin level became normal in 4 patients in 12 months and in 10 patients in 18 to 24 months. In the Liv.52 group, the serum globulin level became normal in 4 patients in 12 months and in 10 patients in 18 to 24 months. The results after the entire study were as follows: Infective hepatitis: The results were graded as good, fair, and poor in 73.33%, 23.33%, and 3.33% of the patients, respectively, in the Liv.52 group, and 26.66%, 66.66%, and 6.66% of the patients, respectively, in the control group. Chronic active hepatitis: The results were graded as good, fair, and poor in 37.50%, 50.00%, and 12.50% of the patients, respectively, in the Liv.52 group, and 0%, 50%, and 50% of the patients, respectively, in the control group. Liver cirrhosis: The results were graded as good, fair, and poor in 21.05%, 52.63%, and 26.32% of the patients, respectively, in the Liv.52 group, and 0%, 37.5%, and 62.5% of the patients, respectively, in the control group. No adverse effects were reported in the patients treated with Liv.52. Thus, Liv.52 was considered safe. Conclusion The treatment with Liv.52 appeared to be highly promising in patients with liver diseases such as liver cirrhosis, chronic active hepatitis, and infective hepatitis. Summary • In this study, a total of 104 patients were included, of whom 73 patients were treated with Liv.52, and 31 patients constituted the control group; the liver diseases studied were liver cirrhosis, chronic active hepatitis, and infective hepatitis. • The clinical improvement in symptoms was quicker in the Liv.52 group compared with that in the control group. • Among the patients with infective hepatitis treated with Liv.52, the results were graded as good, fair, and poor in 73.33%, 23.33%, and 3.33% of the patients, respectively. • Among the patients with chronic active hepatitis treated with Liv.52, the results were considered good, fair, and poor in 37.50%, 50.00% and 12.50% of the patients, respectively. • Among the patients with liver cirrhosis treated with Liv.52, the results were graded as good, fair, and poor in 21.05%, 52.63%, and 26.32% of the patients, respectively. • Liv.52 was found to be safe and effective in the treatment of liver diseases. Efficacy of Liv.52 in the Management of Infective Hepatitis, Chronic Active Hepatitis, and Cirrhosis
RkJQdWJsaXNoZXIy MjAwNDg=